IDH2 and glioma: A meta-analysis including 714 patients demonstrated that the median overall survival of patients with IDH-wildtype gliomas harboring homozygous CDKN2A deletion was 13.0 months, compared with 18.0 months in patients without the deletion (p = 0.014, log-rank test) (41, 42).